Tenofovir disoproxil fumarate ( TDF ) use has been associated with declines in the estimated glomerular filtration rate ( eGFR ) when used as part of antiretroviral treatment by persons with human immunodeficiency virus ( HIV ) type 1 , but limited data are available for risk when used as preexposure prophylaxis ( PrEP ) for HIV-1 prevention .